Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)

Influenza Infection Clinical Trial

Official title:

A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Influenza Virus

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05818124
• Other study ID #: 4482-019
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: August 21, 2023
• Est. completion date: June 28, 2024

Study information

• Verified date: May 2024
• Source: Merck Sharp & Dohme LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of molnupiravir (MK-4482) in healthy participants inoculated with experimental influenza virus. The primary hypotheses are that MK-4482 initiated 12 hours following intranasal inoculation of the influenza challenge virus reduces the peak viral load compared to placebo and that MK-4482 initiated 2 days following intranasal inoculation of the influenza challenge virus reduces the viral load area under the curve (AUC) compared to placebo.

Description:

This study has two parts. Part 1 is an open-label validation study, with a cohort of 20 untreated participants undergoing nasal inoculation with the A/France/759/21 [H1N1] strain on Day 0 to confirm viral infectivity and disease. Part 2 will be a randomized, double-blind placebo- and active-comparator-controlled study where participants will be inoculated on Day 0 with either the A/France/759/21 [H1N1] virus used in Part 1 or an alternative influenza virus. Part 2 will evaluate the antiviral efficacy, pharmacokinetics, and safety of MK-4482 in participants inoculated with the challenge virus.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 160
• Est. completion date: June 28, 2024
• Est. primary completion date: June 28, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Is in good health based on medical history, physical examination, vital sign measurements, spirometry, and electrocardiograms performed before inoculation.

• Has a total body weight =50 kg and Body Mass Index (BMI) =18 kg/m^2 and =35 kg/m^2.

• For males: abstains from heterosexual intercourse as their preferred and usual lifestyle and agrees to remain abstinent OR uses contraception unless confirmed to be azoospermic.

• For participants assigned female sex at birth: is not pregnant or breastfeeding, AND is either not a person of childbearing potential (POCBP) or is a POCBP AND uses a contraceptive method that is highly effective (low user dependency method, OR a user dependent hormonal method in combination with barrier method), or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle, has a negative highly sensitive pregnancy test, abstains from breastfeeding, and has medical, menstrual, and recent sexual activity history reviewed by the investigator to decrease risk of early undetected pregnancy.

Exclusion Criteria:

• Has a history of, or has currently active, symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to admission to quarantine.

• Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases.

• Is mentally or legally incapacitated, has significant emotional problems at the time of prestudy visit, or expected during the conduct of the study, or has a history of clinically significant psychiatric disorder of the last 5 years.

• Has a history of cancer.

• Has a history of rhinitis which is clinically active, or history of moderate to severe rhinitis, or history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal corticosteroids on an at least weekly basis, within 30 days prior to admission to quarantine.

• Has a history of atopic dermatitis/eczema which is clinically severe and/or requiring moderate to large amounts of daily dermal corticosteroids.

• Has a diagnosis of cluster headache/migraine or is receiving prophylaxis against migraine.

• Has a lifetime history of anaphylaxis and/or a lifetime history of severe allergic reaction. Significant intolerance to any food or drug in the last 12 months.

• Has had major surgery and/or donated or lost 1 unit of blood within 3 months prior to the prestudy visit.

• Uses or anticipates the use of concomitant medications, including vitamins or herbal and dietary supplements from approximately 2 weeks prior to the planned date of viral challenge until the poststudy visit.

• Has evidence of receipt of vaccine within the 4 weeks prior to the planned date of viral challenge.

• Intends to receive any vaccine(s) before the last day of follow-up.

• Has received any investigational drug within 3 months prior to the planned date of viral challenge.

• Has received 3 or more investigational drugs within the previous 12 months prior to the planned date of viral challenge.

• Has had prior inoculation with a virus from the same virus subtype as the challenge virus.

• Has had prior inoculation with a virus from the same virus-family as the challenge virus in the last 12 months.

• Has had prior participation in another human viral challenge study with a respiratory virus in the preceding 3 months, taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study.

• Has smoked =10 pack-years at any time.

• Has a recent history or presence of alcohol addiction, or excessive use of alcohol.

• Consumes excessive amounts, defined as more than 6 servings of caffeinated beverages or xanthine-containing products.

• Has any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and, in particular, any of the nasal assessments or viral challenge.

• Has any clinically significant history of epistaxis.

• Has had any nasal or sinus surgery within 3 months.

• Is a regular user of cannabis or any illicit drugs, or has a history of drug abuse within approximately 1 year.

Related Conditions & MeSH terms

• Influenza Infection
• Influenza, Human

Intervention

Drug:
• Molnupiravir
Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
• Placebo molnupiravir
Four placebo capsules matched to molnupiravir taken twice daily by mouth.
• Placebo oseltamivir
Placebo capsule matched to oseltamivir taken twice daily by mouth.
• Oseltamivir
One capsule of oseltamivir 75 mg taken twice daily by mouth.

Biological:
• Influenza A Virus
Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).

Locations

Country	Name	City	State
United Kingdom	hVIVO Services ( Site 0001)	London	London, City Of

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Infectivity Rate Based on Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) Day 1 to Discharge	The proportion of participants with two quantifiable (=lower limit of quantitation (LLOQ)) influenza challenge virus qRT-PCR measurements reported on =2 independent nasopharyngeal samples over 2 days.	From Day 1 afternoon up to Day 8
Primary	Part 1: Infectivity Rate Based on qRT-PCR Day 2 to Discharge	The proportion of participants with two quantifiable =LLOQ influenza challenge virus qRT-PCR measurements reported on =2 independent nasopharyngeal samples over 2 days.	From Day 2 afternoon up to Day 8
Primary	Part 1: Number of participants experiencing =1 viral challenge-related adverse event (AE)	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE is viral challenge-related as determined by investigator.	From Day 0 to Day 31
Primary	Part 2, Panel A: Peak Viral Load (PVL) by Quantitative Viral Culture	PVL is the maximum viral load of influenza challenge virus from nasopharyngeal samples to be determined by quantitative viral culture.	From Day 1 afternoon up to Day 8
Primary	Part 2, Panel B: Area Under the Viral Load-Time Curve (VL-AUC) by Quantitative Viral Culture	VL-AUC is the area under the viral load-time curve of influenza challenge virus nasopharyngeal samples to be determined by quantitative viral culture.	From Day 2 morning up to Day 8
Secondary	Part 1: Quantitative Viral Culture-Confirmed Influenza Infection Day 1 to Discharge	The proportion of participants with one quantifiable =LLOQ influenza challenge virus measurement from quantitative viral culture from a nasopharyngeal sample.	From Day 1 afternoon up to Day 8
Secondary	Part 1: Quantitative Viral Culture-Confirmed Influenza Infection Day 2 to Discharge	The proportion of participants with one quantifiable =LLOQ influenza challenge virus measurement from quantitative viral culture from a nasopharyngeal sample.	From Day 2 afternoon up to Day 8
Secondary	Part 1: VL-AUC by Quantitative Viral Culture Day 1 to Discharge	VL-AUC is the area under the viral load-time curve of influenza challenge virus nasopharyngeal samples to be determined by quantitative viral culture.	From Day 1 afternoon up to Day 8
Secondary	Part 1: VL-AUC by qRT-PCR Day 1 to Discharge	VL-AUC is the area under the viral load-time curve of influenza challenge virus nasopharyngeal samples to be determined by qRT-PCR.	From Day 1 afternoon up to Day 8
Secondary	Part 1: VL-AUC by Quantitative Viral Culture Day 2 to Discharge	VL-AUC is the area under the viral load-time curve of influenza challenge virus nasopharyngeal samples to be determined by quantitative viral culture.	From Day 2 afternoon up to Day 8
Secondary	Part 1: VL-AUC by qRT-PCR Day 2 to Discharge	VL-AUC is the area under the viral load-time curve of influenza challenge virus nasopharyngeal samples to be determined by qRT-PCR.	From Day 2 afternoon up to Day 8
Secondary	Part 1: PVL by qRT-PCR Day 1 to Discharge	PVL is the maximum viral load of influenza challenge virus from nasopharyngeal samples to be determined by qRT-PCR.	From Day 1 afternoon up to Day 8
Secondary	Part 1: PVL by Quantitative Viral Culture Day 1 to Discharge	PVL is the maximum viral load of influenza challenge virus from nasopharyngeal samples to be determined by quantitative viral culture.	From Day 1 afternoon up to Day 8
Secondary	Part 1: PVL by qRT-PCR Day 2 to Discharge	PVL is the maximum viral load of influenza challenge virus from nasopharyngeal samples to be determined by qRT-PCR.	From Day 2 afternoon up to Day 8
Secondary	Part 1: PVL by Quantitative Viral Culture Day 2 to Discharge	PVL is the maximum viral load of influenza challenge virus from nasopharyngeal samples to be determined by quantitative viral culture.	From Day 2 afternoon up to Day 8
Secondary	Part 1: Duration of Quantifiable Influenza by qRT-PCR Day 1 to Discharge	Time in days from the first quantifiable (=LLOQ) influenza challenge virus measurement until the first confirmed unquantifiable (	From Day 1 afternoon up to Day 8
Secondary	Part 1: Duration of Quantifiable Influenza by Quantitative Viral Culture Day 1 to Discharge	Time in days from the first quantifiable (=LLOQ) influenza challenge virus measurement until the first confirmed unquantifiable (	From Day 1 afternoon up to Day 8
Secondary	Part 1: Duration of Quantifiable Influenza by qRT-PCR Day 2 to Discharge	Time in days from the first quantifiable (=LLOQ) influenza challenge virus measurement until the first confirmed unquantifiable (	From Day 2 afternoon up to Day 8
Secondary	Part 1: Duration of Quantifiable Influenza by Quantitative Viral Culture Day 2 to Discharge	Time in days from the first quantifiable (=LLOQ) influenza challenge virus measurement until the first confirmed unquantifiable (	From Day 2 afternoon up to Day 8
Secondary	Part 1: Area Under the Total Symptom Score-Time Curve (TSS-AUC) Day 1 to Discharge	TSS-AUC as measured by graded symptom scoring system collected 3 times daily. Each symptom is graded where a higher grade represents a higher symptom intensity/impact.	From Day 1 morning up to Day 8
Secondary	Part 1: TSS-AUC Day 2 to Discharge	TSS-AUC as measured by graded symptom scoring system collected 3 times daily. Each symptom is graded where a higher grade represents a higher symptom intensity/impact.	From Day 2 middle of the day to up to Day 8
Secondary	Part 1: Peak Total Symptom Score (TSS) Day 1 to Discharge	Maximum TSS as measured by graded symptom scoring system collected 3 times daily.	From Day 1 morning up to Day 8
Secondary	Part 1: Peak TSS Day 2 to Discharge	Maximum TSS as measured by graded symptom scoring system collected 3 times daily.	From Day 2 middle of the day up to Day 8
Secondary	Part 1: Duration in Days of Grade =2 Symptoms Day 1 to Discharge	Duration of time in days from the first occurrence of any symptom assigned Grade 2 or higher, to the beginning of the first 24-hour period without any symptom assigned Grade 2 or higher, after the peak TSS.	From Day 1 morning up to Day 8
Secondary	Part 1: Duration in Days of Grade =2 Symptoms Day 2 to Discharge	Duration of time in days from the first occurrence of any symptom assigned Grade 2 or higher, to the beginning of the first 24-hour period without any symptom assigned Grade 2 or higher, after the peak TSS.	From Day 2 middle of the day up to Day 8
Secondary	Part 1: Time in Days to Symptom Resolution Day 1 to Discharge	Time in days from the beginning of the specified time frame until the beginning of a 24-hour period with no symptoms above the baseline maximum TSS, as measured by graded symptom scoring system collected 3 times daily. Baseline maximum is defined as the maximum TSS on Day -1.	From Day 1 morning up to Day 8
Secondary	Part 1: Time in Days to Symptom Resolution Day 2 to Discharge	Time in days from the beginning of the specified time frame until the beginning of a 24-hour period with no symptoms above the baseline maximum TSS, as measured by graded symptom scoring system collected 3 times daily. Baseline maximum is defined as the maximum TSS on Day -1.	From Day 2 middle of the day up to Day 8
Secondary	Part 1: Time in Days to Peak Daily Maximum TSS Day 1 to Discharge	Time in days from the beginning of the specified time frame to the time of the peak daily maximum TSS.	From Day 1 morning up to Day 8
Secondary	Part 1: Time in Days to Peak Daily Maximum TSS Day 2 to Discharge	Time in days from the beginning of the specified time frame to the time of the peak daily maximum TSS.	From Day 2 middle of the day up to Day 8
Secondary	Part 2, Panel A: VL-AUC by Quantitative Viral Culture	VL-AUC is the area under the viral load-time curve of influenza challenge virus nasopharyngeal samples to be determined by quantitative viral culture.	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: VL-AUC by qRT-PCR	VL-AUC is the area under the viral load-time curve of influenza challenge virus nasopharyngeal samples to be determined by qRT-PCR.	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: PVL by qRT-PCR	PVL is the maximum viral load of influenza challenge virus from nasopharyngeal samples to be determined by qRT-PCR.	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: qRT-PCR-Confirmed Influenza Infection	The proportion of participants witht wo quantifiable (= LLOQ) influenza challenge virus qRT-PCR measurements reported on =2 independent nasopharyngeal samples over 2 days.	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: qRT-PCR-Confirmed Symptomatic Influenza Infection	The proportion of participants with two quantifiable (= LLOQ) influenza challenge virus qRT-PCR measurements reported on =2 independent nasopharyngeal samples over 2 days AND TSS =2 at =1 time point following inoculation.	From Day 1 morning up to Day 8
Secondary	Part 2, Panel A: qRT-PCR-Confirmed Moderately Severe Symptomatic Influenza Infection	The proportion of participants with two quantifiable (= LLOQ) influenza challenge virus qRT-PCR measurements reported on =2 independent nasopharyngeal samples over 2 days AND any symptom of Grade =2 at =1 timepoint following inoculation.	From Day 1 morning up to Day 8
Secondary	Part 2, Panel A: qRT-PCR-Confirmed Febrile Influenza Infection	The proportion of participants with two quantifiable (= LLOQ) influenza challenge virus qRT-PCR measurements reported on =2 independent nasopharyngeal samples over 2 days AND temperature of =37.9 degrees Celsius at =1 timepoint following inoculation.	From Day 1 morning up to Day 8
Secondary	Part 2, Panel A: Quantitative Viral Culture-Confirmed Influenza Infection	The proportion of participants with one quantifiable =LLOQ influenza challenge virus measurement from quantitative viral culture from a nasopharyngeal sample.	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: Quantitative Viral Culture-Confirmed Symptomatic Influenza Infection	The proportion of participants with one quantifiable =LLOQ influenza challenge virus measurement from quantitative viral culture from a nasopharyngeal sample AND TSS =2 at =1 timepoint following inoculation.	From Day 1 morning up to Day 8
Secondary	Part 2, Panel A: Duration of Quantifiable Influenza by qRT-PCR	Time in days from the first quantifiable (=LLOQ) influenza challenge virus measurement until the first confirmed unquantifiable (	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: Duration of Quantifiable Influenza by Quantitative Viral Culture	Time in days from the first quantifiable (=LLOQ) influenza challenge virus measurement until the first confirmed unquantifiable (	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: Time in Days to Confirmed Negative Test by qRT-PCR	Time in days from the beginning of the specified time frame until the first confirmed unquantifiable (	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: Time in Days to Confirmed Negative Test by Quantitative Viral Culture	Time in days from the beginning of the specified time frame until the first confirmed unquantifiable (	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: Time in Days to Peak Viral Load by qRT-PCR	Time in days from the beginning of the specified time frame until the peak viral load measurement to be determined by qRT-PCR.	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel A: Time in Days to Peak Viral Load by Quantitative Viral Culture	Time in days from the beginning of the specified time frame until the peak viral load measurement to be determined by quantitative viral culture.	From Day 1 afternoon up to Day 8
Secondary	Part 2, Panel C: VL-AUC by Quantitative Viral Culture	VL-AUC is the area under the viral load-time curve of influenza challenge virus nasopharyngeal samples to be determined by quantitative viral culture.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel B & C: VL-AUC by qRT-PCR	VL-AUC is the area under the viral load-time curve of influenza challenge virus nasopharyngeal samples to be determined by qRT-PCR.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel B & C: PVL by qRT-PCR	PVL is the maximum viral load of influenza challenge virus from nasopharyngeal samples to be determined by qRT-PCR.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel B & C: PVL by Quantitative Viral Culture	PVL is the maximum viral load of influenza challenge virus from nasopharyngeal samples to be determined by quantitative viral culture.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel B & C: Duration of Quantifiable Influenza by qRT-PCR	Time in days from the first quantifiable (=LLOQ) influenza challenge virus measurement until the first confirmed unquantifiable (	From Day 2 morning up to Day 8
Secondary	Part 2, Panel B & C: Duration of Quantifiable Influenza by Quantitative Viral Culture	Time in days from the first quantifiable (=LLOQ) influenza challenge virus measurement until the first confirmed unquantifiable (	From Day 2 morning up to Day 8
Secondary	Part 2, Panel B & C: Time in Days to Confirmed Negative Test by qRT-PCR	Time in days from the beginning of the specified time frame until the first confirmed unquantifiable (	From Day 2 morning up to Day 8
Secondary	Part 2, Panel B & C: Time in Days to Confirmed Negative Test by Quantitative Viral Culture	Time in days from the beginning of the specified time frame until the first confirmed unquantifiable (	From Day 2 morning up to Day 8
Secondary	Part 2, Panel B & C: Time in Days to Peak Viral Load by qRT-PCR	Time in days from the beginning of the specified time frame until the peak viral load measurement to be determined by qRT-PCR.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel B & C: Time in Days to Peak Viral Load by Quantitative Viral Culture	Time in days from the beginning of the specified time frame until the peak viral load measurement to be determined by quantitative viral culture.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel A: TSS-AUC Day 1 to Discharge	TSS-AUC as measured by graded symptom scoring system collected 3 times daily. Each symptom is graded where a higher grade represents a higher symptom intensity/impact.	From Day 1 morning up to Day 8
Secondary	Part 2, Panel B & C: TSS-AUC Day 2 to Discharge	TSS-AUC as measured by graded symptom scoring system collected 3 times daily. Each symptom is graded where a higher grade represents a higher symptom intensity/impact.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel A: Peak TSS Day 1 to Discharge	Maximum TSS as measured by graded symptom scoring system collected 3 times daily.	From Day 1 morning up to Day 8
Secondary	Part 2, Panel B & C: Peak TSS Day 2 to Discharge	Maximum TSS as measured by graded symptom scoring system collected 3 times daily.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel A: Daily Maximum TSS Day 1 to Discharge	Maximum TSS on each day, measured by graded symptom scoring system.	3 times daily from the morning of Day 1 through Day 8
Secondary	Part 2, Panel B & C: Daily Maximum TSS Day 2 to Discharge	Maximum TSS on each day, measured by graded symptom scoring system.	3 times daily from the morning of Day 1 through Day 8
Secondary	Part 2, Panel A: Duration in Days of Grade =2 Symptoms Day 1 to Discharge	Duration of time in days from the first occurrence of any symptom assigned Grade 2 or higher, to the beginning of the first 24-hour period without any symptom assigned Grade 2 or higher, after the peak TSS.	From Day 1 morning up to Day 8
Secondary	Part 2, Panel B & C: Duration in Days of Grade =2 Symptoms Day 2 to Discharge	Duration of time in days from the first occurrence of any symptom assigned Grade 2 or higher, to the beginning of the first 24-hour period without any symptom assigned Grade 2 or higher, after the peak TSS.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel A: Time in Days to Symptom Resolution Day 1 to Discharge	Time in days from the beginning of the specified time frame until the beginning of a 24-hour period with no symptoms above the baseline maximum TSS, as measured by graded symptom scoring system collected 3 times daily. Baseline maximum is defined as the maximum TSS on Day -1.	From Day 1 morning up to Day 8
Secondary	Part 2, Panel B & C: Time in Days to Symptom Resolution Day 2 to Discharge	Time in days from the beginning of the specified time frame until the beginning of a 24-hour period with no symptoms above the baseline maximum TSS, as measured by graded symptom scoring system collected 3 times daily. Baseline maximum is defined as the maximum TSS on Day -1.	From Day 2 morning up to Day 8
Secondary	Part 2, Panel A: Time in Days to Peak Daily Maximum TSS Day 1 to Discharge	Time in days from the beginning of the specified time frame to the time of the peak daily maximum TSS.	From Day 1 morning up to Day 8
Secondary	Part 2, Panel B & C: Time in Days to Peak Daily Maximum TSS Day 2 to Discharge	Time in days from the beginning of the specified time frame to the time of the peak daily maximum TSS.	From Day 2 morning up to Day 8
Secondary	Part 2, Panels A & B: Number of Participants with One or More AE	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.	Up to 31 days
Secondary	Part 2, Panels A & B: Number of Participants who Discontinue Study Drug Due to an AE	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.	Up to day 8
Secondary	Part 2, Panels A & B: Number of Participants with One or More Viral Challenge-Related AE	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE is viral challenge-related as determined by investigator.	Up to 31 days
Secondary	Part 2, Panels A & B: Number of Participants with Viral Challenge-Related Concomitant Medication Use	The number of participants who use at least 1 concomitant medication.	Up to 31 days
Secondary	Part 2, Panels A & B: Maximum Plasma Concentration (Cmax) of N-hydroxycytidine (NHC)	The Cmax of NHC will be reported.	Day (D) 0, D2, D4: predose D5: predose, 0.5, 1.5, 4, 8, 12, 24, 48, 72 hours post morning dose
Secondary	Part 2, Panels A & B: Time to Maximum Plasma Concentration (Tmax) of NHC	The Tmax of NHC will be reported.	Day (D) 0, D2, D4: predose D5: predose, 0.5, 1.5, 4, 8, 12, 24, 48, 72 hours post morning dose
Secondary	Part 2, Panels A & B: Half Life (t1/2) of NHC	The t1/2 of NHC will be reported.	Day (D) 0, D2, D4: predose D5: predose, 0.5, 1.5, 4, 8, 12, 24, 48, 72 hours post morning dose
Secondary	Part 2, Panels A & B: Area Under the Plasma Concentration From 0 to 12 Hours Postdose (AUC0-12) of NHC	The AUC0-12 of NHC will be reported.	Day (D) 0, D2, D4: predose D5: predose, 0.5, 1.5, 4, 8, 12, 24, 48, 72 hours post morning dose
Secondary	Part 2, Panels A & B: Area Under the Plasma Concentration From 0 to Time of the Last Quantifiable Concentration after Dosing (AUC0-last) of NHC	The AUC0-last of NHC will be reported.	Day (D) 0, D2, D4: predose D5: predose, 0.5, 1.5, 4, 8, 12, 24, 48, 72 hours post morning dose
Secondary	Part 2, Panels A & B: Trough Concentration (Ctrough) of NHC	The Ctrough of NHC will be reported.	Day (D) 0, D2, D4: predose D5: predose, 0.5, 1.5, 4, 8, 12, 24, 48, 72 hours post morning dose

External Links

•   Merck Clinical Trials Information